In Brief
Elimination of cancer stem cells in acute myeloid leukemia (AML) while preserving hematopoiesis is a challenge in leukemia treatment. Paris et al. demonstrate that inactivation of the RNA m 6 A reader YTHDF2 increases the half-life of m 6 Amodified transcripts and specifically compromises cancer stem cells, highlighting YTHDF2 as an essential regulator of AML.
INTRODUCTION
Hematopoiesis critically depends on hematopoietic stem cells (HSCs), which possess unique self-renewal capacity and multilineage differentiation potential, replenishing all blood lineages (Orkin and Zon, 2008) . Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem and progenitor cells (HSPCs) in which the acquisition of mutations by HSPCs results in a block in their myeloid differentiation and the generation of self-renewing leukemic stem cells (LSCs) (Dö hner et al., 2015) . LSCs initiate and propagate the disease, and given that they are treatment resistant, they often fuel disease relapses. Therefore, identification of specific therapeutic targets for LSC elimination is an unmet clinical need. Emerging evidence indicates an involvement of mRNA N6-methyladenosine (m 6 A) modification, the most abundant internal mRNA modification (Desrosiers et al., 1974; Perry and Kelley, 1974) , in hematopoietic specification, differentiation, and pathogenesis of AML (Barbieri et al., 2017; Li et al., 2017; Vu et al., 2017; Weng et al., 2018; Zhang et al., 2017) . The m 6 A modification is deposited by the m 6 A methyltransferase complex (m 6 A writer) composed of a METTL3 and METTL14
heterodimeric enzymatic core and their regulator, WTAP (Bokar et al., 1997; Liu et al., 2014; Ping et al., 2014; Tuck, 1992; Wang et al., 2014b) , and reversed by m 6 A demethylases (FTO and AlkBH5; Jia et al., 2011; Zheng et al., 2013) referred to as m 6 A erasers. Recent studies revealed the requirement for METTL3, METTL14, and FTO in leukemic transformation and established the importance of m 6 A modification in AML (Barbieri et al., 2017; Li et al., 2017; Vu et al., 2017; Weng et al., 2018) . However, while m 6 A modification regulates mRNA processing, translation, and degradation (Fu et al., 2014) , the functional contributions of these m 6 A-dependent processes to leukemic transformation have not been explored.
The outcome of RNA m 6 A modification is executed by the YTH (YT521-B homology) domain proteins (known as readers), including nuclear YTHDC1 (Xiao et al., 2016a; Xu et al., 2014) and cytoplasmic YTHDF1-YTHDF3 and YTHDC2 (Shi et al., 2017; Tanabe et al., 2016; Wang et al., 2014a Wang et al., , 2015 . Nuclear YTHDC1 regulates mRNA splicing and nuclear export (Xiao et al., 2016a). While YTHDF1 and YTHDF3 binding to m 6 A enhances mRNA translation (Shi et al., 2017; Wang et al., 2015) , YTHDF2 recognizes m 6 A mRNA within the GACU/A consensus to mediate degradation of m 6 A transcripts (Du et al., 2016; Wang et al., 2015) . Although previous studies perturbing the whole m 6 A pathway have established its significance in AML pathogenesis (Barbieri et al., 2017; Li et al., 2017; Vu et al., 2017; Weng et al., 2018) , the functions of specific m 6 A readers in leukemia remain unexplored. However, recent studies implicated Ythdf2 in the regulation of HSC homeostasis and hematopoietic regeneration (Li et al., 2018; Wang et al., 2018) . Here, we reveal that targeting YTHDF2 extends the half-life of m 6 A-modified transcripts to selectively compromise AML initiation and propagation without derailing normal hematopoiesis.
RESULTS

Ythdf2
Is Essential for LSC Development and AML Initiation We found that YTHDF2 was expressed significantly higher across AML samples with diverse cytogenetic abnormalities compared to non-leukemic controls ( Figure 1A ), and YTHDF2 protein was highly expressed in primary AML samples (Figure 1B) . We next compared YTHDF2 expression in datasets from AML cells with LSC activity and AML cells without LSC activity validated by xenotransplantation (Ng et al., 2016) and found that YTHDF2 expression correlated with LSC activity ( Figure 1C ). Given that the majority of CD34 + and a minority of CD34 À fractions have LSC activity (Eppert et al., 2011; Sarry et al., 2011) , we also compared YTHDF2 expression between these fractions and found that YTHDF2 was expressed at higher levels in CD34 + fractions ( Figure S1A ). To investigate the requirement for YTHDF2 in leukemogenesis, we employed conditional genetics and a mouse AML model in which Meis1 and Hoxa9, oncogenes frequently overexpressed in human AML (Drabkin et al., 2002; Lawrence et al., 1999) , drive leukemogenesis. In this model ( Figure 1D ), HSPCs are transduced with retroviruses co-expressing Meis1 and Hoxa9 and serially replated, generating preleukemic cells, which upon transplantation to recipient mice generate self-renewing LSCs, causing AML (Guitart et al., 2017; Kroon et al., 1998; Vukovic et al., 2015) . We utilized the conditional and reporter Ythdf2 fl mouse allele in which exon 2 of Ythdf2 was flanked by loxP sites and GFP was inserted after the start codon of Ythdf2 in exon 1, generating a fully functional GFP-YTHDF2 fusion protein (Ivanova et al., 2017) . We combined the Ythdf2 fl allele with Vav-iCre (de Boer et al., 2003) Figure 1G ), they had unaffected expression of c-Kit, CD11b, and Gr-1 ( Figure 1H ). Notably, Ythdf2-deficient preleukemic cells generated AML with substantially longer latency compared to control cells (Figures 1I and 1J Figure 1L ). Therefore, Ythdf2 is required for LSC development and AML initiation.
To test whether Ythdf2 is required for leukemic transformation driven by other oncogenes, we used PML-RARA, which causes acute promyelocytic leukemia, and MOZ-TIF2, which is associated with AML with inv(8)(p11q13). Serial replating assays revealed that Ythdf2 CKO c-Kit + cells transduced with either PML-RARA or MOZ-TIF2 retroviruses failed to efficiently generate colonies ( Figure 1M ). Thus, Ythdf2 is essential for leukemic transformation driven also by other oncogenes. Figure 2E ) due to spontaneous Mx1-Cre activation (even without the administration of polyinosinic-polycytidylic acid [pIpC] ) and failed to efficiently engraft and propagate the disease ( Figures 2C and 2D ). Therefore, YTHDF2 is critical for LSC maintenance.
Targeting YTHDF2 Disables Human AML Cells
To investigate the requirement for YTHDF2 in human leukemic cells, we knocked down the expression of YTHDF2 in human AML THP-1 cells harboring MLL-AF9 translocation using two independent short hairpins targeting YTHDF2. YTHDF2 knockdown ( Figure 2F ) inhibited their proliferative capacity ( Figure 2G ) and increased their apoptosis ( Figure 2H ) but had no impact on their myeloid differentiation ( Figure 2I ). This finding was corroborated in NOMO-1 AML cells harboring MLL-AF9 translocation (Figures S1B and S1C). THP-1 cells with YTHDF2 knockdown had compromised capacity to engraft AML ( Figure 2J ) and displayed impaired ability to cause fatal AML ( Figure 2K ). Finally, we performed knockdown experiments in independent human primary AML samples and found that YTHDF2 depletion significantly decreased the clonogenic potential of AML cells in colony-forming cell (CFC) assays (Figures 2L and 2M Figure 3B ). Apart from a decrease in CD8 + T cells,
Ythdf2
CKO mice had essentially normal numbers of differentiated cells in their spleens ( Figure S2B ). We found unaffected numbers of granulocyte/macrophage progenitors (GMPs), increased numbers of pre-megakaryocyte/erythroid progenitors (preMegEs) and megakaryocyte progenitors (MkPs) and an imbalance between pre-colony forming unit-erythroid (pre-CFU-E) and colony forming unit-erythroid (CFU-E) ( Figure S2C ). CFC assays showed normal differentiation potential of Ythdf2 CKO BM cells ( Figure 3C ). Thus, YTHDF2 is not critical for steady-state hematopoiesis.
Ythdf2 Loss Results in HSC Expansion
We next investigated the impact of Ythdf2 deletion on stem and progenitor cells. Adult Ythdf2 CKO mice displayed expansion of LSK cells, HSCs, and HPC-1 and HPC-2 progenitor cells compared to Ythdf2 CTL mice ( Figures 3D and 3E ). We also inducibly ablated Ythdf2 using Mx1-Cre, which upon pIpC injection acutely deletes Ythdf2 in Ythdf2 iCKO adult mice ( Figure 3F ).
Acute Ythdf2 deletion ( Figure 3G ) had no impact on mouse survival (data not shown) or multilineage hematopoiesis (Figures 3H and 3I; Table S1 ) and resulted in increased numbers of LSK cells, but not myeloid progenitor cells ( Figure 3J ). Thus, hematopoiesis-specific Ythdf2 ablation during development or acute deletion in adult mice leads to an expansion of the primitive cell compartment at the top of the hematopoietic hierarchy and does not derail normal hematopoiesis.
To reveal the repopulation capacity of Ythdf2-deficient HSCs, we competitively transplanted HSCs from Ythdf2 CKO and
Ythdf2
CTL mice into lethally irradiated recipients. HSCs of both genotypes gave equal overall long-term reconstitution (Figure 3K ). However, while Ythdf2 CKO HSCs had enhanced myeloid lineage reconstitution capacity, they had normal B cell and compromised T cell reconstitution potentials ( Figure 3K ). Strikingly, Ythdf2 CKO HSCs displayed significantly increased capacity to contribute to the BM HSC and progenitor cell compartments and differentiated cell compartments ( Figures 3L and 3M ). The analyses of donor-derived compartment of the recipients revealed increased frequencies of Ythdf2 CKO LSK, HPC-1, and HPC-2 cells ( Figure S2D ). The myeloid bias of Ythdf2-deficient HSCs and its connection to a shift in balance among the HSCs, MPP, and HPC populations upon Ythdf2 deletion merit future investigation. Therefore, targeting Ythdf2 promotes stem or primitive progenitor cell expansion and enhances their reconstitution and myeloid differentiation potentials.
YTHDF2 Decreases m 6
A RNA Stability in AML We next sought to understand the mechanism by which YTHDF2 loss impedes LSC function. YTHDF2 is known to promote transcript decay through deadenylation (Du et al., 2016; Wang et al., 2014a) . Indeed, the loss of YTHDF2 resulted in deregulated gene expression with 754 upregulated and 528 downregulated genes; p < 0.05) in Ythdf2 CKO compared to Ythdf2 CTL preleukemic cells ( Figure 4A ). Gene Ontology analysis of deregulated genes in preleukemic cells revealed generic metabolic processes in the upregulated genes and immune response processes in the downregulated genes ( Figure S3A ). To understand which of the deregulated transcripts could be direct targets of YTHDF2, we determined transcriptome-wide mRNA m 6 A in 4G ). We next employed ribosome profiling (RIBO-seq; Reid et al., 2015) to measure translational efficiency that did not grossly alter between the respective genotypes ( Figure 4H ). YTHDF2 deficiency did not alter the translational efficiency of either m 6 A or non-m 6 A-containing transcripts (Figure 4I) . These data indicate that m 6 A-directed YTHDF2-mediated mRNA decay contributes to the regulation of the leukemic transcriptome.
Next, we sought to determine if the m 6 A-modified transcripts deregulated upon Ythdf2 deletion in mouse AML are relevant to human AML. We found that transcripts significantly upregulated in the Ythdf2 CKO preleukemic cells are preferentially methylated in human AML cell lines ( Figure 4J ). To understand the molecular pathways underpinned by upregulated transcripts methylated both in mouse and human, we performed ConcensusPathDB (C) CFU assays performed with BM cells from 8-to 10-wk-old mice. CFU-Red, CFU-erythroid and/or megakaryocyte; CFU-G, CFU-granulocyte; CFU-M, CFUmonocyte/macrophage; CFU-GM, CFU-granulocyte and monocyte/macrophage; CFU-Mix, at least three of the following: granulocyte, erythroid, monocyte/ macrophage, and megakaryocyte (n = 4). (CPDB) network analysis and found enrichment for RNA processing, mitochondrial function, ubiquitination as well as tumor necrosis factor (TNF) signaling (Figures 4K and S3I) . To reveal why the loss of YTHDF2 is correlated with a weak leukemogenic potential, we interrogated gene sets from human AML samples associated with different leukemogenic potential in vivo (Ng et al., 2016) . The upregulated transcripts in Ythdf2 CKO preleukemic cells that contain m 6 A in both mouse and human AML cells were divided into groups whose expression positively or negatively correlates with YTHDF2 expression in 1,732 human AML samples (Figure S3I) . We found that transcripts that negatively correlate with YTHDF2 expression are highly associated with the loss of leukemogenic potential ( Figure 4L ). In this way, when an AML sample expresses low amounts of YTHDF2, transcripts associated with the loss of leukemogenic potential have greater expression. In contrast, transcripts whose expression correlates with that of YTHDF2 are depleted from transcripts associated with weak LSC activity ( Figure S3J ). Thus, YTHDF2 negatively regulates transcripts whose expression limits LSC activity.
Ythdf2 Deletion Sensitizes AML Cells to TNF Inspecting the genes that negatively correlate with YTHDF2 expression in human AML, contain m 6 A in both mouse and human AML, are upregulated in Ythdf2 CKO LSCs, and are associated with weak LSC function, we found TNF receptor 2 (TNFR2) encoded by Tnfrsf1b gene ( Figure 4L ). We focused on TNFR2, as TNF signaling was also identified as a node in the CPDB network analysis ( Figure 4K ) and TNFR2, together with TNFR1, restricts the accumulation of leukemic cells (Hö ckendorf et al., 2016) . TNFRSF1B expression is significantly decreased in AML samples compared to non-leukemic controls ( Figure S3K) , and its expression negatively correlates with LSC activity (Figure S3L) . Notably, TNFRSF1B is highly methylated in mouse preleukemic cells and human AML cells ( Figure 4M ). RNA immunoprecipitation (RIP)-qPCR revealed co-precipitation of the Tnfrsf1b transcript with YTHDF2 ( Figure 4N ). Concurrent with the increased half-life of Tnfrsf1b transcript (Figure 4O ), the surface expression of TNFR2 is upregulated on Ythdf2 CKO preleukemic cells ( Figure 4P ). We therefore tested if TNF stimulation had differential impact on Ythdf2 CTL and Ythdf2 CKO preleukemic cells. YTHDF2 loss rendered cells more sensitive to TNF-induced apoptosis ( Figure 4Q ). This highlights at least one molecular mechanism by which YTHDF2 loss negatively impacts AML.
DISCUSSION
Through the analysis of mRNA m 6 A methyltransferases and demethylase, a key role for mRNA m 6 A has been shown in AML pathogenesis (Barbieri et al., 2017; Li et al., 2017; Vu et al., 2017; Weng et al., 2018) . The modification of mRNA with m 6 A can have multiple outcomes on the respective transcript , but here we demonstrate that the YTHDF2-mediated A reader YTHDF2 as a critical mediator of LSCs whose inhibition selectively compromises AML implying its future applications in treatment of this hematological malignancy.
STAR+METHODS
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STAR+METHODS METHOD DETAILS
Flow cytometry All BM and FL cells were prepared and analyzed as described previously (Guitart et al., 2017; Guitart et al., 2013; Kranc et al., 2009; Mortensen et al., 2011; Vukovic et al., 2016) . BM cells were isolated by crushing tibias and femurs using a pestle and mortar. FL cells were prepared by mashing the tissue and passing through a 70mm strainer. Single cell suspensions from BM, FL or PB were incubated with Fc block and then stained with antibodies. For HSC and progenitor cell analyses, following incubation with Fc block, unfractionated BM cells were stained with lineage markers containing biotin-conjugated anti-CD4, anti-CD5, anti-CD8a, anti-CD11b, anti-B220, anti-Gr-1 and anti-Ter119 antibodies together with APC-Cy7-conjugated anti-c-Kit, Pacific Blue-conjugated anti-Sca-1, PE-conjugated anti-CD48 and PE-Cy7-conjugated anti-CD150 antibodies. Biotin-conjugated antibodies were then stained with PerCP-conjugated streptavidin. For analyses of differentiated cells, following incubation with Fc block, spleen or BM cell suspensions were stained with PerCP-conjugated anti-B220 and APC-Cy7-conjugated anti-CD19 antibodies for B cells; Pacific Blue-conjugated anti-CD11b and PE-Cy7-conjugated anti-Gr-1 for myeloid cells; APC-conjugated anti-CD8 antibodies and PE-conjugated anti-CD4 antibodies for T cells. To distinguish CD45.2 + -donor derived cells in PB or BM of transplanted mice, BV711-conjugated anti-CD45.1 and Pacific Blueconjugated anti-CD45.2 antibodies were used. For HSC and progenitor staining in transplanted mice, APC-conjugated anti-c-Kit, and APC-Cy7-conjugated anti-Sca-1 were used; the remainder of the staining was as described above. For analyses of differentiated cells in BM of transplanted mice, myeloid cells were stained with PE-conjugated anti-CD11b, PE-Cy7-conjugated anti-Gr-1 and APC-conjugated anti-Ter119 for erythroid cells. Lymphoid cells were stained separately, as described above. PB of transplanted mice was stained with BV711-conjugated anti-CD45.1, Pacific Blue-conjugated anti-CD45.2, PE-conjugated anti-CD4 and-CD8a, PE-Cy7-conjugated anti-Gr-1, APC-conjugated anti-CD11b, and APC-Cy7-conjugated anti-CD19. TO-PRO-3 or DAPI were used for dead cell exclusion. Flow cytometry analyses were performed using a LSRFortessa (BD). Cell sorting was performed on a FACSAria Fusion (BD).
Colony forming cells (CFC) assays
CFC assays were carried out using MethoCultTM M3434 (STEMCELL Technologies) methylcellulose medium. Two technical replicates were used per each biological replicate in each experiment. Colonies were tallied at day 10. Human primary AML samples were enumerated after 7 days of culture in semisolid medium in the presence of recombinant IL-6, G-CSF and TPO (20ng/ml) using puromycin as the selectable marker.
Leukemic transformation c-Kit + cells were prepared from FLs of 14.5 dpc embryos using c-Kit (CD117) enrichment with MACS columns (Miltenyi Biotec).
200,000 c-Kit + cells were co-transduced with MSCV-Meis1a-puro and MSCV-Hoxa9-neo retroviruses. Transduced cells were subjected to three rounds of CFC assays in MethoCultTM M3231 (STEMCELL Technologies) supplemented with 20ng/ml SCF, 10ng/ml IL-3, 10ng/ml IL-6 and 10ng/ml GM-SCF. Colonies were counted 5 days after plating, and 2,000 cells were re-plated.
Syngeneic transplantation assays CD45.1 + /CD45.2 + recipient mice were lethally irradiated using a split dose of 11 Gy (two doses of 5.5 Gy administered at least 4 hours apart) at an average rate of 0.58 Gy/min using a Cesium 137 GammaCell 40 irradiator. Xenotransplantation experiments THP-1 cells transduced with CTL or KD lentiviruses were tail vein injected into non-irradiated 12 week-old female non-obese diabetic (NOD)/LtSz-severe combined immune-deficiency (SCID) IL-2Rgc null (NSG) mice (1x10 6 cells per 200 mL per mouse). Mice were killed one month after transplantation. For survival curve analyses, 10,000 or 1,000 cells per NSG mouse were injected. To assess human AML burden, cells were stained with anti-human PE-conjugated anti-CD45 and APC-conjugated anti-CD33.
pIpC administration
Mice were injected intraperitoneally every other day with 300 mg pIpC (GE Healthcare) for a total of 6 doses, as previously described (Guitart et al., 2017; Guitart et al., 2013; Kranc et al., 2009 0 -TTCTCCGAACGTGTCACGTT-3 0 ; GE Healthcare). Selection of efficiently transduced cells was achieved by treatment with puromycin (2 mg/mL final concentration).
Cell proliferation, cell death and cell differentiation analyses Lentivirus-transduced THP-1 were seeded at 15x10 4 /mL after puromycin selection. Viable cells were counted by trypan blue exclusion at the indicated time points. To analyze cells undergoing apoptosis, cells were suspended in binding buffer containing Annexin V-PE and DAPI. To assess myeloid differentiation, cells were stained with PE-conjugated anti-CD14 and APC-conjugated anti-CD11b antibodies.
Primary human AML patient derived samples For western blotting shown in Figure 1B , the following samples were used: 70 (karyotype 46,XY,del (7) (6)t(6;9),der(9)t(6;9)del(9)(q21q34)[2]).
Western blotting
Proteins extracted from CTL, KD1 and KD2 THP-1 cells were subjected to SDS-PAGE (Bolt 4%-12% Bis-Tris Plus Gel, ThermoFisher Scientific, NW04120BOX) and then transferred onto a polyvinylidene fluoride membranes. Membranes were blocked in 10% milk-PBST (PBS with 0.1% Tween20) and probed with anti-YTHDF2 (1:5000, ON at 4 C) and anti-Histone3 (1:5000, 1h at room temperature). After incubation with appropriate horseradish peroxidase-coupled secondary antibody, proteins were detected with SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific, 34075) and acquired on the Amersham Imager 600 (GE Healthcare life Sciences). Affymetrix RNA extraction from Meis1/Hoxa9-transduced c-Kit + cells was performed using TRIzol (Thermo Fisher Scientific). Total RNA was used to synthesize Biotinylated cDNA with the Ambion WT Expression kit (Ambion, 4491974). cDNA was fragmented and labeled with the Affymetrix, WT Terminal and Control Kits (Affymetrix, 901524) and then hybridized for 16 hours at 45 C on a GeneChip Mouse Gene 2.0 ST Array. The chip was later washed and stained with the Affymetrix Fluidics Station 450. Data were processed and analyzed using the Bioconductor Limma Package (Ritchie et al., 2015) . Samples were normalized using the rma function and differential expression was assessed using linear modeling. Log2-fold-changes and moderated t-statistics were calculated using the contrasts.fit function. To determine the gene ontology (GO) enrichment of differentially expressed genes, we used the topGO R package. Fisher's exact test was used to assess enrichment for the biological process ontology.
Analyses of YTHDF2 expression in human AML samples To generate Figure 1A the following publicly available datasets were used: GSE10358, GSE52891, GSE61804, GSE68833, GSE12417, GSE13159, GSE15061, GSE15434, GSE16015, GSE19577, and GSE22845 (Bachas et al., 2015; Haferlach et al., 2009 Haferlach et al., , 2010 Klein et al., 2009; Metzeler et al., 2008; Metzelder et al., 2015; Mills et al., 2009; Pigazzi et al., 2011; Taskesen et al., 2011; Tomasson et al., 2008) . Exclusion criteria included datasets with less than 20 samples, samples with undefined tissue of origin, cell type and karyotype, in addition to RAEB samples. Only BM samples, with a total of 1732 samples were retained for further analysis. The Simpleaffy package from Bioconductor was used to extract quality measurement of microarrays (Gentleman et al., 2004; Wilson and Miller, 2005) . RNA degradation was assessed based on 3 0 to 5 0 ratio of GAPDH and ACTNB genes. Samples with NUSE < 1.05 and relative log expression (RLE) < 0.15 were excluded from further analysis (McCall et al., 2011) . The retained samples were assessed for their homogeneity using the Bioconductor arrayQualityMetrics package (Kauffmann et al., 2009 ). Low quality RNA and outlier samples were excluded, while high quality samples retained after quality control were background corrected and normalized using RMAexpress software (http://rmaexpress.bmbolstad.com/). Pairwise comparisons between each karyotype and control were performed using Student's t test. et al., 2015) and peaks were called using MACS2 (Zhang et al., 2008) . To analyze the distribution of peaks along the transcripts, bedgraph files were converted to bigWig format and used as input for the computeMatrix function of the deepTools package (Ramírez et al., 2014) . Motif enrichment was done using HOMER selecting a motif length of 6 nucleotides. Background regions were generated by shuffling peaks along the transcriptome using the shuffleBed tool from the BEDtools suite (Quinlan and Hall, 2010) . Network analysis was performed using the ConsensusPathDB (CPDB) software (Kamburov et al., 2013) . For gene set enrichment analysis (GSEA), the GSE76008 dataset (Ng et al., 2016) was used to rank genes according to the engraftment potential of pre-leukemic cells. The GVIZ bioconductor package was used for peak visualization (Hahne and Ivanek, 2016) . Correlation with YTHDF2 was measured to determine robust YTHDF2 targets after the knockout (Må nsson et al., 2004) . Briefly, Pearson correlation between YTHDF2 and the identified YTHDF2 targets was calculated using the 1732 AML samples previously described. Correlation significance was measured using parametric test with length (genes)-2 degrees of freedom (cor.test function, stats package, R project, http://www.R-project.org/), and adjusted for multiple comparisons using Benjamini & Hochberg method (Benjamini and Hochberg, 1995) . Genes with negative coefficients and adjusted p value < 0.05 were considered strong targets of YTHDF2.
SLAM-seq SLAM-seq libraries were prepared using the Lexogen catabolic kit (cat. no. 062.24) and the Lexogen QuantSeq 3 0 mRNA-Seq Library Prep Kit FWD for Illumina (cat. no. 015.24) in both cases following manufacturers' instructions. S4U was used at 2.9 mM, as determined by the cell viability titration assay. Medium with 4SU was used for pre-leukemic cells labeling for 12 hours and was later replaced with 4SU-free medium (time 0). Cells were collected immediately after medium change and at 1, 3, and 9 hours. Libraries were sequenced using an Illumina HiSeq platform in a 50 bp single-end mode. Biological triplicates for both Ythdf2 CTL and Ythdf2 cKO pre-leukemic cells were used to generate the different libraries sets. SLAM-seq libraries were analyzed as previously described (Herzog et al., 2017) . Briefly, T to C conversion rates were obtained using the SlamDunk pipeline. Conversion rates across different time points were normalized to time 0 for each gene and were used to fit a first order decay reaction with the R stats package nls function.
RIBO-seq RIBO-seq libraries were prepared as previously described (Reid et al., 2015) . Briefly, pre-leukemic cells were lysed with CaCl 2 4 mM, MgCl 10 mM, K-HEPES pH 7.2 25 mM, KOAc 200 mM and NP-40 1%. The lysate was cleared from cell debris, diluted 1:1 in water, and digested with MNase 10 mg/ml for 30 minutes at 37 C. Digested RNA was extracted with QIAzol and later treated with PNK (NEB) for 30 minutes at 37 C. To isolate ribosome-protected mRNA fragments (RPFs), the PNK-treated RNA was resolved on a 15% Novex TBE-Urea Gel (EC6885BOX), and RPFs 25 to 40 nucleotides long were excised and purified. Libraries were then prepared using the NEBNextÒ Multiplex Small RNA Library Prep Set for Illumina following manufacturer's instructions. For input controls, total RNA was extracted from the pre-leukemic cell lysates before MNase digestion using QIAzol. Samples were then depleted of ribosomal RNA using the Epicenter Ribo-zero kit (cat. no. MRZH116), and libraries were generated using the SENSE Total RNA-Seq Library Prep Kit (cat no. 009.08) following manufacturer's instructions. Libraries were sequenced with the Illumina HiSeq platform in a 50 bp singleend mode. Biological triplicates were used to generate libraries for both Ythdf2 CTL and Ythdf2 cKO pre-leukemic cells. For the RIBOseq analysis, we used Kallisto (Bray et al., 2016) to obtain read counts per gene for the RPF and mRNA libraries. Read counts were then used to calculate the differential translational efficiency between Ythdf2 CTL and Ythdf2 cKO pre-leukemic cells with Xtail (Xiao et al., 2016b) . To estimate the relative translational efficiency for genes in each condition, we compared RPF and mRNA read counts using DESeq2 (Love et al., 2014) .
DATA AND SOFTWARE AVAILABILITY Accession
Affymetrix, m 6 A meRIP-Seq, RIBO-seq and SLAM-seq datasets were deposited in ArrayExpress under the following accession numbers: E-MTAB-6783, E-MTAB-7782, E-MTAB-6791, E-MTAB-7783, E-MTAB-7785 and E-MTAB-7784. Data from NOMO-1 and MA9.3ITD human cell lines were obtained from previously published work (Su et al., 2018) through the following accession number: GSE87190.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc.). P values were calculated using a two-tailed Mann-Whitney U test unless stated otherwise. Kaplan-Meier survival curve statistics were determined using the Log-rank (Mantel Cox) test.
